Table 1 Summary table of the meta-analysis
Auther(year) | Country | Samplesize(N) (F/M) | Cutoff value | Age (range) | Follow-up (median) | Detection method | Outcomes | Quality assessment |
|---|---|---|---|---|---|---|---|---|
Buccheri et al. [17] | Italy | 286(31/255) | 0.5 g/mL | 61 (32–87) | 34 months | Latex assay | OS | 7 |
Taguchi et al. [18] | Japan | 70 | 150 ng/ml | 65 (20–83) | 15 months | ELISA | OS | 5 |
Ferrigno et al. [19] | Italy | 343(31/304) | 0.5 ug/ml | 68 (39–86) | - | Immunoturbidimetry | OS | 8 |
Pavey et al. [20] | Australia | 166(38/128) | 32.99 ng/ml | 64 (30–86) | 270 days | ELISA | OS | 8 |
Buccheri et al. [21] | Italy | 826(99/727) | 0.5 ug/ml | 67 (35–89) | 34 weeks | Immunoturbidimetry | OS | 8 |
Altiay et al. [23] | Turkey | 78(5/73) | 0.65 ug/ml | 61 (37–82) | 264 days | ELISA | OS | 8 |
Komurcuoglu et al. [24] | Turkey | 100(14/86) | 1250 ng/dl | 67 | - | ELISA | OS | 6 |
Masago et al. [25] | Japan | 99(28/71) | 0.6 ng/ml | 72(35–88) | 0–800 days | ELISA | OS | 8 |
Ay et al. [26] | Austria | 182 | 0.84 g/mL | 62 (52–68) | 731 days | Latex assay | OS | 7 |
Tas et al. [2] | Turkey | 110(10/100) | 360 IU/ml | 59(35–80) | 20.3 weeks | Microparticle Enzyme Immunoassay | OS | 7 |
Zhang et al. [27] | China | 232 (83/149) | 0.3 ug/ml | 61(30–86) | 47.0 months | Immunoturbidimetry | OS | 6 |
Fukumoto et al. [28] | Japan | 237(85/152) | 0.50 lg/ml | 69(31–85) | 51.6 months | - | OS | 7 |
Ursavaş et al. [29] | Turkey | 65 (10/55) | 375 μg/L | 60 | 0–1,000 days | Latex assay | OS | |
Ge et al. [30] | China | 82(27/55) | - | 64 (44–72) | - | Immunoturbidimetry | OS/PFS | 8 |
Inal et al. [9] | Turkey | 72(16/56) | 1900 ng/mL | - | 574.14 days | ELISA | OS | 8 |
Wang et al. [31] | China | 1929(604/1325) | 0.5 μg/mL | - | 18.0 months | Immunoturbidimetry | OS/PFS | 7 |
Chen et al. [22] | China | 393(71/322) | 0.5 ug/ml | 57(49–65) | 12 months | Immunoturbidimetry | OS/PFS | 6 |
Zhu et al. [32] | China | 74(17/57) | 0.55 ug/L | 57(42–80) | 11.5 months | Immunoturbidimetry | OS/PFS | 8 |
Jiang [33] | China | 107(23/84) | 0.55 mg/L | 63.0(58.5,68.0) | 9 months | Immunoturbidimetry | OS | 8 |
Sun [18] | China | 272(109/163) | 0.55 mg/L | 65 | - | - | OS | 6 |
Zhang et al. [34] | China | 160(31/129) | 500 ng/ml | 59 (23–83) | - | Immunoturbidimetry | PFS | 8 |
Fan et al. [35] | China | 82(15/67) | 0.55 mg/L | 60(28–82) | 0–50 months | Immunoturbidimetry | PFS/OS | 8 |
Hou et al. [36] | China | 395(170/225) | 0.20 mg/L | 64(56–69) | 13.2 months | Immunoturbidimetry | OS | 6 |
Liang et al. [37] | China | 456(138/318) | 500 ng/ml | 61(35–81) | 42 months | Immunoturbidimetry | OS | 8 |
Shiina et al. [38] | Japan | 235(89/146) | 1.0 μg/ml | 70 | 0–3 years | - | OS | 8 |
Chen et al. [15] | China | 233(70/1630) | 500 mg/ml | 67 | 0–60 months | ELISA | OS | 7 |
Liu et al. [16] | China | 651(216/435) | 0.5 mg/L | 60 | 0–80 months | Immunoturbidimetry | OS | 7 |
Moik et al. [39] | Russia | 277(103/174) | 1 mg/dl | 61(56–67) | 24 months | Latex assay | OS/PFS | 8 |
Auther(year) | Treatment | Histology type | Disease stage (T0/T1/T2/T3/T4) | ||||
|---|---|---|---|---|---|---|---|
Chemotherapy (alone/combination) | Radiotherapy | Chemo-radiation | Surgery | No anticancer treatment or supportive care | |||
Buccheri et al. [17] | - | - | - | - | E/S/A/L/U 112/37/67/18/52 | I/II/III/IV 42/31/119/94 | |
Taguchi et al. [18] | 50 | 20 | 0 | NSCLC 49; SCLC 21 | - | ||
Ferrigno et al. [19] | 175 | 8 | - | 66 | 26% | E/A/S/L/U 125/80/34/16/88 | I/II/III/IV 69/26/124/121 |
Pavey et al. [20] | - | - | - | - | - | NSCLC 166(A/E/L/O 68/76/13/9) | - |
Buccheri et al. [21] | E/S/A/L/U 296/93/210/48/179 | I/II/III/IV /149/57/310/305 | |||||
Altiay et al. [23] | 74 | 57 | - | 4 | NSCLC 60; SCLC 18 | III/IV 35/43 | |
Komurcuoglu et al. [24] | - | - | - | - | NSCLC 87; SCLC 13 | II/III/IV 15/50/35 | |
Masago et al. [25] | 67 | 2 | 8 | - | 22 | A/E/N 68/18/13 | III/IV42/57 |
Ay et al. [26] | - | - | - | - | - | - | - |
Tas et al. [2] | E/A/U/S 26/30/28/16 | ||||||
Zhang et al. [27] | - | - | - | 232 | - | E/A 111/121 | I-II/III 173/59 |
Fukumoto et al. [28] | - | - | - | 237 | - | E/A/L/O 51/162/7/17 | - |
Ursavaş et al. [29] | - | - | - | - | - | E/A/S/U 32/11/17/5 | I/II/III/IV 20/5/16/32 |
Ge et al. [30] | 82 | - | - | - | - | N-SCC/SCC 53/29 | IIIB/IV 10/72 |
Inal et al. [9] | 72 | - | - | - | - | E/A/N/S 19/14/24/15 | III/IV 33/22 |
Wang et al. [31] | - | - | - | - | - | A/O 1046/885 | IV1929 |
Chen et al. [22] | 126 | - | 267 | - | - | SCLC 393 | - |
Zhu et al. [32] | 74 | - | - | - | - | SCLC 74 | - |
Jiang [33] | 25 | - | 82 | - | - | SCLC 107 | - |
Sun [18] | 177 | - | - | - | - | N-SCLC 272 | IV 272 |
Zhang et al. [34] | 160 | - | - | - | - | SCLC 160 | LD/ED 38/122 |
Fan et al. [35] | 27 | - | 51 | - | - | SCLC 82 | I + II + IIIa/IIIb + IV 19/63 |
Hou et al. [36] | - | - | - | 395 | - | NSCLC(E/A/O) 53/329/13 | I-II/III 341/54 |
Liang et al. [37] | - | - | - | 456 | - | NSCLC 61 | I/II/III 170/101/185 |
Shiina et al. [38] | 46 | 2 | 9 | 235 | - | Adenocarcinoma/Squamous cell carcinoma/LCNEC/Large cell carcinoma/Pleomorphic carcinoma/Carcinoid 186/55/2/2/2/2 A/E/L/L/P/C 186/55/2/2/2/2 | - |
Chen et al. [15] | - | - | - | - | - | E/A/O 55/124/54 | III/IV 110/123 |
Liu et al. [16] | 492 | 70 | 89 | E/A/O 126/504/21 | III/IV98/553 | ||
Moik et al. yy[39] | 277 | 277 | - | 277 | - | NSCLC/SCLC 231/46 | I/II/III/IV 1/4/76/196 |